Want to see TSE:DOSE full AI Analyst Report?
DOSE Stock Chart & Stats
C$0.12
<C$0.01(5.56%)
At close: 4:00 PM EDT
C$0.12
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume11.00K
Average Volume (3M)27.76K
Market Cap
C$12.28M
Enterprise ValueC$20.79M
Total Cash (Recent Filing)C$14.65K
Total Debt (Recent Filing)C$5.81M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Feb 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume23,050
30 Day Avg. Volume27,763
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)C$35.30M
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformThe proprietary QuickStrip platform provides a differentiated delivery format with potential convenience benefits across pharmaceuticals, nutraceuticals, and other active compounds. Its broad formulation scope can support repeated applications and partner opportunities, creating a basis for durable technology-led growth.
Asset-Light Commercial ModelA commercialization model centered on licensing, royalties, and development services can reduce the need to build a large integrated manufacturing and sales organization. If partnerships scale, milestone and royalty income could expand platform reach while preserving operating leverage.
Positive Recent Cash FlowPositive trailing operating and free cash flow is a constructive sign that the business has recently generated some cash internally despite its reported losses. This may provide limited support for ongoing operations and partner development, although the small amount requires continued execution.
Bears Say
Weak Revenue EconomicsShrinking revenue combined with negative gross profit indicates that current commercialization has not yet produced attractive underlying economics. Persistent operating and net losses can consume resources, limit reinvestment, and make it harder for the platform to achieve sustainable scale over the coming quarters.
Stressed Balance SheetNegative shareholders’ equity materially reduces financial flexibility and signals that liabilities exceed the recorded equity base. Meaningful debt relative to assets may constrain funding choices, increase solvency pressure, and leave the company less able to absorb operating setbacks or finance expansion.
Unstable Cash GenerationAlthough recent cash flow was positive, its small scale relative to net losses and sharp deterioration from the prior period weaken confidence in its durability. If cash generation remains inconsistent, the company may need to rely more heavily on financing or partnership proceeds to sustain operations.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$12.28M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Feb 01, 2027 which is in 99 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Rapid Dose Therapeutics Corp released its earnings results on Jun 29, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 136,444,840 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Rapid Dose Therapeutics Corp reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
―
Telescope Innovations Corp
―